Edwards Lifesciences Corp (NYSE:EW) Shares Bought by Huntington National Bank
Huntington National Bank increased its stake in Edwards Lifesciences Corp (NYSE:EW) by 5.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 309,218 shares of the medical research company’s stock after acquiring an additional 16,728 shares during the quarter. Edwards Lifesciences makes up 0.9% of Huntington National Bank’s holdings, making the stock its 26th largest holding. Huntington National Bank owned about 0.15% of Edwards Lifesciences worth $57,125,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Pinnacle Bank acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth $65,000. Cetera Advisor Networks LLC grew its holdings in shares of Edwards Lifesciences by 3.8% during the fourth quarter. Cetera Advisor Networks LLC now owns 1,573 shares of the medical research company’s stock valued at $242,000 after buying an additional 57 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Edwards Lifesciences during the first quarter valued at $843,000. Wendell David Associates Inc. grew its holdings in shares of Edwards Lifesciences by 1.7% during the second quarter. Wendell David Associates Inc. now owns 12,100 shares of the medical research company’s stock valued at $2,235,000 after buying an additional 207 shares in the last quarter. Finally, Wetherby Asset Management Inc. grew its holdings in shares of Edwards Lifesciences by 11.5% during the first quarter. Wetherby Asset Management Inc. now owns 3,273 shares of the medical research company’s stock valued at $626,000 after buying an additional 337 shares in the last quarter. Institutional investors and hedge funds own 81.95% of the company’s stock.
In related news, CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $174.73, for a total transaction of $5,731,144.00. Following the transaction, the chief executive officer now directly owns 75,926 shares in the company, valued at $13,266,549.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Larry L. Wood sold 6,716 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $176.34, for a total value of $1,184,299.44. Following the transaction, the vice president now owns 122,495 shares in the company, valued at $21,600,768.30. The disclosure for this sale can be found here. Insiders have sold 180,491 shares of company stock worth $33,096,783 over the last 90 days. Corporate insiders own 1.63% of the company’s stock.
Shares of Edwards Lifesciences stock traded up $0.38 during trading on Friday, reaching $212.85. The company’s stock had a trading volume of 1,380,656 shares, compared to its average volume of 1,395,143. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.69 and a current ratio of 3.38. The stock has a fifty day moving average price of $190.15. The company has a market cap of $44.30 billion, a price-to-earnings ratio of 45.29, a price-to-earnings-growth ratio of 2.68 and a beta of 0.85. Edwards Lifesciences Corp has a one year low of $134.53 and a one year high of $219.71.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.05. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the previous year, the company posted $1.24 earnings per share. The firm’s revenue for the quarter was up 15.2% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Corp will post 5.33 EPS for the current fiscal year.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Story: What is meant by holder of record?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.